VasCog Virtual 2021

Highlights

PROGRAMME

11:45 - 12:45 - Oral Session I

Breakout Room 1: Biomarkers I -SVD Pathophysiology (Talks 5 min each)

Chairs: Chris Chen (Singapore), Perminder Sachdev (Australia) 

  1. Association of type 2 diabetes, according to the number of risk factors within target range, with structural brain abnormalities, cognitive performance and risk of dementia- April van Gennip (The Netherlands)
  2. Cerebrospinal fluid biomarkers, brain structural and cognitive performances between normotensive and hypertensive controlled, uncontrolled and untreated 70-year-old adults- Atef Badji (USA)
  3. Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration with high plasma SPP1 associated with short patient survival- Sebastian Lewandowski (Sweden)
  4. AIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the prevent-dementia- Audrey Low (UK)
  5. The impact of Alzheimer biomarkers and vascular factors on cognitive decline in memory clinic patients- Veerle van Gils (The Netherlands)
  6. Validation of a novel clinical neurovascular coupling biomarker- Suzanne E. van Dijk (The Netherlands)
  7. Analyzing multimodal MRI at tract-level with neural networks enhances the prediction of cognitive performance in memory clinic patients with small vessel disease- Alberto De Luca (The Netherlands)
  8. Network-based lesion impact score is an independent predictor of post-stroke cognitive impairment- J. Matthijs Biesbroek (The Netherlands)
  9. Relationship between cerebrovascular pathology and resting-state functional connectivity: a systematic review- Natasha Clarke (Canada)

Breakout Room 2: Stroke, Cognition and Pathophysiology (Talks 5 min each)

Chairs: Ingmar Skoog (Sweden), Louise Allan (Exeter) 

  1. Trajectories of cognitive change following stroke: a stepwise decline towards dementia- Joao Delgado (UK)
  2. Long-Term Outcomes Among Nigerian Stroke Survivors - the CogFAST-Nigeria Study- Gabriel Ogunde (Nigeria)
  3. Brain regions involved in the strategic processes of verbal fluency: a mVLSM study in 337 stroke patients- Flore Dorchies (France)
  4. Patterns and predictors of short-term trajectory of post-stroke cognitive function- Jess Lo (Australia)
  5. Visuospatial dysfunction in Vascular Cognitive impairment subtypes- A comparative study from a tertiary care center in Kolkata- Ashwani Bhat (India)
  6. Pure vascular-ischemic disease and cognitive impairment - Elisabet Englund (Sweden)
  7. Association between Cerebral Small Vessel Disease and Alzheimer’s disease pathologies- Yuan Cai (China)
  8. Combined associations of cognitive and motor impairments with functional outcome in covert cerebral small vessel disease- Hanna Jokinen (Finland)
  9. Cerebral small vessel function in patients with CADASIL and sporadic cerebral small vessel disease: assessment of hemodynamic response function with 7T MRI– the Zoom@svds study, Hilde van den Brink (The Netherlands)

12:50 - 13:00 - Welcome/ Opening (10 min)

Convenors: Raj Kalaria, John O’Brien, Hugh Markus (UK)


13:00 - 13:30 - Plenary I

Clinical VCI: J Wardlaw (UK) 20 min with 10 min discussion

Chair: John O/Brien (UK)


13:30 - 14:45 - Symposium I

The importance of VRF and Heart Variability for Cognition and Dementia: 

Chairs: K Ikram and D Bos (The Netherlands)

  • Orthostatic hypotension/heart failure and dementia - Frank Wolters (The Netherlands) (12 min)
  • Heart rate variability/blood pressure variability and cognition/dementia -Yuan Ma (USA) (12 min)
  • Cardiac dysfunction and cognition/dementia - Saima Hilal (Singapore) (12 min)
  • Cardiac biomarkers: current state-of-the-art - Thomas Vanassche (Belgium) (12 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. Visit-to-Visit Variability in Blood Pressure over 10 Years, Cognitive Decline and Incident Dementia in Three Community-Based Cohorts of Older Adults- Simin Mahinrad (USA)
  2. Investigating the risk of cardiovascular risk factor subgroups in cognitively normal elderly on Alzheimer’s disease: a latent class approach- Myuri Ruthirakuhan (Canada)

Discussion


14:30 - 15:30 - E-poster Blitz session I

Chair:  Adrian Wong (Hong Kong)

  1. Prevalence of cognitive impairment and dementia in  a multi-ethnic elderly cohort the Singapore Epidemiology of Eye Diseases study (SEED)- Ting Pang (Singapore)
  2. Discriminant Validity of the Progressive Forgetfulness Question in a Stepwise Dementia Screening Approach in a Singaporean Elderly Population- Ting Pang (Singapore)
  3. Neurofilament light level correlates with brain atrophy and cognitive and motor performance in subjects with cerebral white matter hyperintensities- Marge Kartau (Finland)
  4. Age-associated changes in the renin-angiotensin system: implications for future clinical trials- Robert MacLachlan (UK)
  5. Renin-angiotensin system gene expression and dementia pathology in Alzheimer’s disease, vascular and mixed dementia- Hannah Tayler (UK)
  6. Angiotensinogen, ACE-1 and ACE-2 in Alzheimer’s disease and vascular dementia- Özge Güzel (UK)
  7. Fibrinogen activates microglia and drives extracellular vesicle mediated propagation of pro-inflammatory signaling- Austyn Roseborough (Canada)
  8. Relationships between Myeloperoxidase and the Cognitive and Neuroimaging Correlates of Mild Vascular Cognitive Impairment- Kritleen Bawa (Canada)
  9. Modelling Alzheimer’s Disease through Environmentally Induced Neurovascular Dysfunction within an In Vitro Cell Model- Ernesto Zarate-Aldrete (UK)
  10. Endothelin-1-mediated contraction of human brain pericytes is dysregulated in the presence of Aβ1-40- Elliott Hibbs (UK)
  11. Automatic quantification of perivascular spaces in T2-weighted images at 7T MRI- Hugo Kuijf (The Netherlands)
  12. Connection Between Kidney Function and Cognition in the Elderly- Tomas Månsson (Sweden)
  13. Low carotid end diastolic velocity is associated with white matter hyperintensities and cortical atrophy in the Swedish "Good Aging in Skane" study- Katarina Ellström (Sweden)
  14. Association of cerebral small vessel disease burden with brain structure and cognitive and vascular risk trajectories in mid-to-late life- Michelle G. Jansen (The Netherlands)
  15. Self-reported cognitive decline, emotional symptoms, and daytime sleep after ischemic stroke- Elisabeth Kliem (Norway)
  16. Social Cognition is Associated with General Cognitive Function Post-Stroke- Elise Gjestad (Norway)
  17. Prevalence of, and risk factors for, vascular cognitive impairment in CADASIL- Amy A Jolly (UK)

 15:30 - 16:00 - Break


16:00 - 17:00 - Symposium II 

Is Brain Inflammation relevant for VCI?

Chairs: Frank Eric de Leeuw (Netherlands) John O’Brien (UK)

  • PET studies of microglial activation and blood brain barrier dysfunction in SVD - Hugh Markus (UK) (15 min)
  • Reprogramming of the peripheral immune system in SVD - Niels Riksen (The Netherlands) (15 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. A cluster of blood-based biomarkers reflecting extracellular matrix organization, inflammation and signal transduction relates to cerebral blood flow in patients with cardiovascular disease - L Malin Overmars (The Netherlands)
  2. Does 11C-PK11195 binding predict lesion growth at one year?- Daniel Tozer (UK)

Discussion


17:00 - 17:30 - Plenary II

Brain vascular extracellular matrix and VCIG Rosenberg (USA) - 20 min with 10 min discussion

Chair:  Eric Smith (Canada)


17:30 - End of Day 1

 
 

08:20 - 08:30 - Welcome/ Opening (10 min)


08:30 - 09:00 - Plenary III

Genetics of Stroke and VCI-from discovery to clinical applications: M Dichgans (Germany)- 20 min 10 min discussion

Chair: Hugh Markus (UK)


09:00 - 10:00 - Symposium III

Cardiovascular risk management throughout the life course to prevent/treat dementia:

Chairs: M Muller & E Richard (The Netherlands)

  • Prevention of dementia: a life-course approach - Majon Muller (The Netherlands) (5min)
  • CVRM to prevent dementia - Edo Richard (The Netherlands) (15 min)
  • CVRM to treat dementia - Majon Muller (The Netherlands) (10 min)

2 x ECR on related topics (5 mins each)

  1. Pulsatility index outperforms conventional imaging markers in the association with cognition in community elderly - Withdrawn
  2. A systematic review into the relationship between blood pressure variability and grey and white matter structures - Daria Gutteridge (Australia)

Discussion


10:00 - 10:10 - Viewpoint session

Aducanumab for Alzheimer's Disease: Anders Wallin (Sweden); Response: Vincent Mok (Hong Kong, China)


10:10 - 10:30 - Coffee Break


10:30 - 11:00 - Plenary IV

Risk Factors for SVD: an Asian Perspective: H-J Bae (S Korea)- 20 min 10 min discussion

Chair: SangYun Kim (S Korea)


11:00 - 12:00 - E-poster Blitz session II (3 min each)

Chair: Deborah Gustafson (USA)

  1. Association Between Blood Pressure Variability with Dementia and Cognitive Impairment: A Systematic Review and Meta-analysis- Philip Tully (Australia)
  2. The Relationship of Acute Delirium with Cognitive and Psychiatric symptoms: A longitudinal study- Vilde Nerdal (Norway)
  3. Neuropsychiatric symptoms accelerate cognitive impairment associated with small vessel disease- Anne Arola (Finland)
  4. Systemic endothelial function and cerebral microbleeds: a cross-sectional analysis within the Rhineland study- Gokhan Pehlivan (Germany)
  5. The brain renin-angiotensin system is altered in age and Alzheimer’s disease- Robert MacLachlan (UK)
  6. The relationship between cognitive reserve and change in cognition during the first three months post-stroke- Ragnhild Roaldsnes
  7. Metabolic syndrome is associated with poor cognition: a population-based study of 70-year-olds without dementia- Anna Marseglia (Sweden)
  8. Small and large MRI-visible perivascular spaces in the basal ganglia of Parkinson’s disease patients- Stephanie Berberian (Canada)
  9. Microstructural changes in the penumbras of cerebral small vessel disease lesions are associated with cognition and sleep- Joel Ramirez (Canada)
  10. Venous Collagenosis, White Matter Hyperintensity and the Perivascular Space - David Lahna (USA)
  11. Serum Placental Growth Factor as a Marker of Cerebrovascular Disease burden in patients with Alzheimer’s Disease- Liu-Yun Wu (USA)
  12. Higher total cholesterol in APOEe4 carriers contributes to Alzheimer’s disease risk: findings from the Alzheimer’s disease Neuroimaging Initiative- Michelle Dunk (USA)
  13. Does white matter hyperintensity location predict cognitive impairment in an elderly population?- Polly Roads (UK)
  14. Prevalence and correlates of white matter hyperintensities in Royal Canadian Air Force pilots and Aircrew- Joel Ramirez (Canada)
  15. Gait and Falls in Cerebral Amyloid Angiopathy- Breni Sharma (Canada)

12:05 - 12:35 - Plenary V

Gait as a biomarker for VCI: Joe Verghese (USA) - 20 min 10 min discussion

Chair: Suvarna Alladi (India)


12:35 - 13:00 - Lunch Break


 13:00 - 14:00 -Early Career Researchers (ECR) Session

"The future of VCI research: a collaborative approach"

Chairs: Hilde van den Brink (The Netherlands), Anna Marseglia (Sweden)

4 x ECR talks (open abstracts, 10 min each)

  1. Diffusion MRI harmonization enables joint-analysis of multicenter data of patients with cerebral small vessel disease – Bruno Miguel Brito Robalo (The Netherlands)
  2. Effects of vascular burden on cognition are mediated by atrophy, amyloid, and glucose metabolism: a multi-centre mixed cohort of small vessel disease and Alzheimer’s pathology- Julie Ottoy (USA)
  3. Risk factors for onset of post-stroke depression in diverse ethno-regional groups- Ben C.P. Lam (Australia)
  4. NOTCH3 variant position is associated with vascular NOTCH3 aggregation load in CADASIL patients- Gido Gravesteijn (The Netherlands)

14:00 - 14:30Plenary VI

Variation in global stroke burden and influence on clinical and brain VCI phenotypes: Implications for prevention: S Seshadri (USA) 20 min with 10 min discussion

Chair:  Sandra Black (Canada)


14:30 - 15:30 - Oral Session II

Breakout Room 1: Biomarkers II - White Matter Pathophysiology, Vascular Reactivity (Talks 5 min each)

Chairs: Geert Jan Biessels (The Netherlands), Eric Smith (Canada) 
  1. Strategic white matter hyperintensity locations for cognitive impairment in memory clinic patients: a large-scaled multicenter study- Mirthe Coenen (The Netherlands)
  2. Strategic white matter hyperintensity locations and cognitive functioning in community-dwelling individuals: rationale and design- Floor A.S. de Kort (The Netherlands)
  3. Sex differences in white matter hyperintensities are modified by menopause: the Rhineland study- Valerie Lohner (Germany)
  4. The association between cardiovascular risk factors and white matter hyperintensity MRI phenotypes- Jasmin A. Keller (The Netherlands)
  5. Cilostazol in Decreasing Progression of Cerebral White Matter Hyperintensities- Bonaventure Ip
  6. The relation between small vessel function and white matter integrity in patients with CADASIL: the zoom@svds study- Naomi Vlegels (The Netherlands)
  7. Vascular reactivity is decreased in early stages of dementia; a novel MRI biomarker- Suzanne E. van Dijk (The Netherlands)
  8. Cerebrovascular reactivity in cerebral amyloid angiopathy- Andrew E Beaudin (Canada)

Breakout Room 2: Blood Brain Barrier Pathophysiology, Models and Dementias - (Talks 5 min each)

Chairs: Marco Duering (Germany), Stuart Allan (UK) (Talks 5 min each)

  1. Uptake and replication of SARS-COV-2 in the cells of the neurovascular unit- Katherine Kellett (UK)
  2. Cognitive impairment post cardiac arrest - reperfusion and hypoperfusion damage- Elisabet Englund (Sweden)
  3. Phosphorylated-tau181 is a Predictor of Poststroke Cognitive Impairment: A Longitudinal Study- Li-Kai Huang, greatoriole@gmail.com
  4. The relationship between late-life hypertension and disease pathology in Alzheimer’s, vascular, and mixed dementia- Hannah Tayler (UK)
  5. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease – a report from the Gothenburg Mild Cognitive Impairment study- Petronella Kettunen (Sweden)
  6. Loss of hippocampal pericytes in vascular dementia, post-stroke dementia and Alzheimer’s disease- Yoshiki Hase (UK)
  7. A cluster of blood-based biomarkers reflecting coagulation relates to the burden of cerebral small vessel disease- Sanne Kuipers (The Netherlands)
  8. Mitochondrial mechanisms and carbonic anhydrases mediate neurovascular dysfunction in CAA models- Silvia Fossati (USA)
  9. A dual potassium channelopathy underlies small vessel disease of the brain in a mouse model of Alzheimer’s disease- Harry Pritchard (UK)

15:30 - 15.40 - Concluding Comments  

VasCog Society Deborah Gustafson (USA); VasCog 2023 Ingmar Skoog (Sweden)

End of day 2 and VasCog 2021 Conference

BREAKOUT SESSIONS

DAY1: ROOM 1

Biomarkers I -SVD Pathophysiology

DAY1: ROOM 2

Stroke, Cognition and Pathophysiology

DAY2: ROOM 1

Biomarkers II - White Matter Pathophysiology, Vascular Reactivity

DAY2: ROOM 2

Blood Brain Barrier Pathophysiology, Models and Dementias

VIDEO HIGHLIGHTS

Day1: Plenary I
Clinical VCI

Day 1: Symposium I
The importance of VRF and Heart Variability for Cognition and Dementia

Day1: E-poster Blitz session I

Day 1: Symposium II
Is Brain Inflammation relevant for VCI?

 Day 1: Plenary II
Brain vascular extracellular matrix and VCI

 Day 2: Plenary III
Genetics of Stroke and VCI- from discovery to clinical applications

Day 2: Symposium III
Cardiovascular risk management throughout the life course to prevent/treat dementia

 Day 2: Viewpoint session
Aducanumabfor Alzheimer’s Disease

 Day 2: Plenary IV
Risk Factors for SVD: an Asian Perspective

Day 2: E-poster Blitz session II

 Day 2: Plenary V
Gait as a biomarker for VCI

 Day 2: Early Career Researchers (ECR) Session
he future of VCI research: a collaborative approach

Day 2: Plenary VI

Variation in global stroke burden and influence on clinical and brain VCI phenotypes: Implications for prevention

 Day 2: Concluding comments
VasCog Society & VasCog 2023

VIRTUAL POSTERS